Topical China Market Research Reports Worked out by CRI Published at

10 Mar 2016 • by Natalie Aster

LONDON - is really pleased to announce that new insightful research studies developed by China Research and Intelligence Co., Ltd. have been recently added to its online catalogue.

Investigation Report on China Fluoxetine Market, 2010-2019. First approved for the treatment of depression in the 1980s in Belgium, Fluoxetine entered the Chinese market in mid-1990s. Since then, the demand for Fluoxetine has been gaining traction. For instance, from 2010 till 2014, the market grew at a 9.68% CAGR. Eli Lilly and Company (Spain), Eli Lilly and Company (Britain), Patheon (FR), Shanghai Zhongxi Pharmaceutical Co., Ltd, Changzhou Siyao Pharmaceutical Co., Ltd, SCCPC, WATSON Pharmaceuticals (Changzhou) Co., Ltd and Shanxi C&Y Pharmaceutical Group Co., Ltd. are amid the most prominent participants in the Chinese Fluoxetine market, with Eli Lilly and Company (Spain) possessing the lion’s share of the market in terms of sales value. As of 2014, its share amounted to 75%.This cutting-edge research report offers an up-close review of the Chinese market for Fluoxetine, investigating the top market participants’ performance. It also provides a granular forecast for the market up to 2019…

Investigation Report on China Methylcobalamin Market, 2010-2019. Methylcobalamin, known under the trade name mecobalamin, introduced by the Eisai Co., Ltd. in Japan in the 1980s, became available in China in 1996. In terms of sales value, the Chinese Methylcobalamin market registered dynamicl growth at a 12.32% CAGR and reached CNY 441 million in 2014, while it stood at CNY 200 million in 2005. Driven by increasing incidence of peripheral neuropathy in the country, the market for Methylcobalamin is expected to remain on the rise in the years to come. Key companies in this market include: Eisai (Suzhou) Pharmaceutical Co., Ltd, Eisai Co., Ltd. (Japan), Jiangsu Sihuan Bioengineering Co., Ltd, Nanjing Hailing Pharmaceutical Co., Ltd. and NCPC. This in-demand research report delves deep into the Chinese Methylcobalamin market scenario, analyzing the currend situation in the market. Moreover, the study provides vital data on the future possible trends of the market for the next several years…

Market Research Report on Aceglutamide in China, 2010-2019. As of the period from 2005 till 2011, the Chinese market for Aceglutamide was unstable and was following a fluctuated trend. Hospitals’ annual sales value was close to CNY 30 million. During 2011-2014, the Chinese Aceglutamide market underwent expansion, with sales growing at a 23.2% CAGR. In 2014, the market sales volume was estimated at more than CNY 40 million. Owing to a potential rise in the demand for central stimulant drugs in China, the Aceglutamide market in the country is likely to continue growing. This comprehensive research publication provides a detailed guide to the Chinese market for Aceglutamide. It offers an insightful overview of the market, details on its sizing, the competitive landscape and sales. The report provides historical data and future projections for the Chinese Aceglutamide marketplace…

Many other research reports by this publisher are published at its China Research and Intelligence Co., Ltd. page


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970